TVTX(Travere Therapeutics, Inc.) · 财务报表

TVTX(Travere Therapeutics, Inc.) 的财务报表:医疗保健,生物技术。数据来自 SEC 公开申报与市场行情,不构成投资建议。

近年年度财务(SEC XBRL)
科目FY 截至 2021-12-31FY 截至 2022-12-31FY 截至 2023-12-31FY 截至 2024-12-31FY 截至 2025-12-31
营业收入$131.84M$109.46M$145.24M$233.18M$490.73M
毛利润$128.02M$105.04M$133.79M$225.43M$480.39M
营业利润−$199.43M−$319.81M−$388.14M−$323.83M−$62.82M
净利润−$180.09M−$278.48M−$111.40M−$321.55M−$25.55M
经营现金流−$14.79M−$186.29M−$280.02M−$237.47M$37.78M
自由现金流−$19.89M−$186.48M−$280.69M——
摊薄每股收益$-3.01$-4.37$-1.50$-4.08$-0.29

Travere Therapeutics, Inc. TVTX